NCT04532125 - SAD and MAD Study With IV and SC Doses of ARGX-117 | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

August 3, 2020

Primary Completion Date

August 26, 2022

Study Completion Date

August 26, 2022

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

ARGX-117

Subjects treated with ARGX-117

OTHER

Placebo

Subjects treated with placebo

BIOLOGICAL

ARGX-117 + rHuPH20

Subjects treated with ARGX-117 + rHuPH20

OTHER

placebo + rHuPH20

Subjects treated with placebo + rHuPH20

BIOLOGICAL

ARGX-117 PH20 SC

Subjects treated with ARGX-117 PH20 SC

OTHER

Placebo PH20 SC

Subjects treated with placebo PH20 SC

Trial Locations (1)

Investigator Site 1, Groningen